Ensol Biosciences Inc. (XKON:A140610) announced a private placement of 472,972 registered convertible preferred shares at a price of KRW 14,800 per share for gross proceeds of KRW 6,999,985,600 on January 8, 2021. The transaction will include participation from new investors Korea Investment & Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd. (KOSE:A006800), NH Investment & Securities Co., Ltd. (KOSE:A005940), and Samsung Securities Co., Ltd. (KOSE:A016360). The shares will be issued at premium to par value of KRW 500 per share. Each preferred share is convertible into a common share between January 16, 2022 and January 15, 2031. The preferred shares bear 1% per annum cumulative and participative dividend. The preferred shares are subject to 1 year hold period. The expected payment date is January 15, 2021 and expected issue date is February 02, 2021. The transaction is approved by the board of directors of the company.